Cryo-Cell International (CCEL) Stock Price, News & Analysis

Company Overview

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

Key Stats

• Today's Range: $7.68 to $7.85
• 50-Day Range: N/A
• 52-Week Range: $4.47 to $9.50
• Volume: 5,450 shs
• Average Volume: 11,103 shs
• Market Capitalization: $63.11 million
• P/E Ratio: N/A
• Dividend Yield: 12.77%
• Price Target: N/A
• Consensus Rating: N/A

CCEL Stock Analysis - Frequently Asked Questions

How were Cryo-Cell International's earnings last quarter?

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) announced its quarterly earnings results on Tuesday, October, 15th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.02 by $0.11. The company earned $8.07 million during the quarter. Cryo-Cell International had a negative trailing twelve-month return on equity of 42.06% and a negative net margin of 28.03%.

Who are Cryo-Cell International's major shareholders?

Top institutional shareholders of Cryo-Cell International include Geode Capital Management LLC (0.49%).
View institutional ownership trends.

How do I buy shares of Cryo-Cell International?

Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Cryo-Cell International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Catalyst Biosciences (CBIO), iClick Interactive Asia Group (ICLK), NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX) and Aspen Group (ASPU).

Company Calendar

• Last Earnings: 10/15/2024
• Ex-Dividend for 11/29 Dividend: 11/15/2024
• Dividend Payable: 11/29/2024
• Today: 12/22/2024
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Miscellaneous health & allied services, not elsewhere classified
• Sub-Industry: Healthcare
• Current Symbol: NYSEAMERICAN:CCEL
• CUSIP: N/A
• CIK: 862692
• Web: www.cryo-cell.com
• Phone: (813) 749-2100
• Fax: 813-855-4745
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,520,000.00
• Net Margins: -28.03%
• Pretax Margin: -38.78%
• Return on Equity: -42.06%
• Return on Assets: 7.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: $31.34 million
• Price / Sales: 2.01
• Cash Flow: $0.64 per share
• Price / Cash Flow: 12.30
• Book Value: ($1.33) per share
• Price / Book: -5.89

Miscellaneous

• Outstanding Shares: 8,060,000
• Free Float: 5,090,000
• Market Cap: $63.11 million
• Optionable: Not Optionable
• Beta: 0.49